Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy

Rupesh Kotecha
_Baptist Health Medical Group; Miami Cancer Institute_, rupeshk@baptisthealth.net

Raees Tonse
_Miami Cancer Institute_, Mohammed.Tonse@baptisthealth.net

Muni Rubens
_Miami Cancer Institute_, MuniR@baptisthealth.net

Haley Appel
_Miami Cancer Institute_, HaleyA@baptisthealth.net

Federico Albrecht
_Baptist Health Medical Group; Miami Cancer Institute_, federicoa@baptisthealth.net

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Citation
Cancers (2021) 13(9):2186
Authors
Rupesh Kotecha, Raees Tonse, Muni Rubens, Haley Appel, Federico Albrecht, Paul Kaywin, Martin Tom, and Minesh Mehta
Systematic Review

Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy

Rupesh Kotecha 1,2,*†, Raees Tonse 1†, Muni Rubens 1, Haley Appel 1, Federico Albrecht 3, Paul Kaywin 3, Evan W. Alley 3, Martin C. Tom 1,2 and Minesh P. Mehta 1,2

Abstract: Malignant pleural mesothelioma (MPM) is a rare cancer with an aggressive disease course. For patients who are medically inoperable or surgically unresectable, multi-agent systemic therapy remains an accepted standard-of-care. The purpose of this meta-analysis is to provide baseline summative survival estimates as well as evaluate the influence of prognostic variables to provide comparative estimates for future trial designs. In this study, a nomogram model was created to estimate survival with treatment with platinum-pemetrexed using covariates known to be associated with survival, including median age, gender, ECOG performance status, tumor stage, and tumor pathology subtype. Collaborative efforts can drive the change in the right direction, and appreciable progress has to be facilitated and newer trial designs may need to pave the way for future innovations in this rare disease.

Simple Summary: Malignant pleural mesothelioma (MPM) is a rare cancer with an aggressive disease course. For patients who are medically inoperable or surgically unresectable, multi-agent systemic chemotherapy remains an accepted standard-of-care. The purpose of this meta-analysis is to provide baseline summative survival estimates as well as evaluate the influence of prognostic variables to provide comparative estimates for future trial designs. In this study, a nomogram model was created to estimate survival with treatment with platinum-pemetrexed using covariates known to be associated with survival, including median age, gender, ECOG performance status, tumor stage, and tumor pathology subtype. Collaborative efforts can drive the change in the right direction, and appreciable progress has to be facilitated and newer trial designs may need to pave the way for future innovations in this rare disease.

1 Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA; Mohammed.tonse@baptisthealth.net (R.T.); MuniR@baptisthealth.net (M.R.); HaleyA@baptisthealth.net (H.A.); MartinTo@baptisthealth.net (M.C.T.); MineshM@baptisthealth.net (M.P.M.)
2 Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA
3 Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA; FedericoA@baptisthealth.net (F.A.); PaulKa@baptisthealth.net (P.K.)
4 Department of Medical Oncology, Cleveland Clinic Florida, Weston, FL 33331, USA; alleye@ccf.org
* Correspondence: rupeshk@baptisthealth.net; Tel.: +1-(786)-527-8140
† These authors given the equal contribution to the manuscript.

Citation: Kotecha, R.; Tonse, R.; Rubens, M.; Appel, H.; Albrecht, F.; Kaywin, P.; Alley, E.W.; Tom, M.C.; Mehta, M.P. Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. Cancers 2021, 13, 2186. https://doi.org/10.3390/cancers13092186

Academic Editors: Daniel L. Pouliquen and Joanna Kopecka

Received: 31 March 2021
Accepted: 30 April 2021
Published: 2 May 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
regimens can be performed using robust survival estimates from prior studies. This study provides baseline comparative values and also allows for accounting for differing proportions of known prognostic variables.

Keywords: mesothelioma; first line; meta-analysis; systematic review

1. Introduction

Malignant pleural mesothelioma (MPM) is a rare cancer with an aggressive disease course associated with poor prognosis [1]. Its incidence in the United States is approximately 3000 new cases diagnosed annually, but is still increasing in the rest of the world, particularly Asia and Europe [2]. Due to its insidious presentation, most patients are diagnosed with locally advanced or metastatic disease-unamenable to radical resection. For patients who are medically inoperable or surgically unresectable, multi-agent systemic chemotherapy remains a current standard-of-care with a median survival of approximately 12 months [3].

Although recent data from the CheckMate 743 trial have demonstrated improved outcomes with first-line immunotherapy [4], the combination of cisplatin and pemetrexed is commonly utilized in the front-line setting worldwide [5,6]. Carboplatin has similar efficacy to cisplatin, with a favorable toxicity profile and ease of administration; therefore, it has often been used in combination with pemetrexed for a large proportion of MPM patients, especially the elderly [7]. The purpose of this meta-analysis is to provide baseline summative survival estimates as well as evaluate the influence of basic prognostic variables to provide comparative estimates for future trial designs.

2. Methods

2.1. Selection of Articles

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) criteria were followed in conducting this systematic review and meta-analysis [8]. The article selection was performed by searching the MEDLINE (PubMed) and Cochrane electronic bibliographic databases for first-line systemic therapy combinations for patients with locally advanced or metastatic MPM. To ensure a comprehensive initial search strategy, generic key words were used in the initial article screen: “mesothelioma” and “locally advanced” and “metastatic” and “first-line” and “systemic therapies” and “platinum/pemetrexed” and “experimental therapies”. Full text articles published in the English language were considered and no publishing date restrictions were used through February 2021.

The initial query identified 447 reports that were subsequently screened by thorough review of the article titles and abstracts, as necessary. Inclusion criteria were publication in the English language, phase II and phase III clinical trials with 10 or more patients evaluable and with published outcomes on the efficacy endpoints of interest. Publications that were available in abstract only form and those in languages other than English were excluded. Case reports and limited case series, preclinical trials, studies using locoregional interventions alone, and studies using second-line therapies, were all excluded. A manual review of the references of the articles that were retrieved was performed to identify additional relevant publications. The search strategy used for this meta-analysis and the methodology for study inclusion is illustrated in Figure S1.

The studies were divided by treatment regimen: platinum-pemetrexed-based treatment and other experimental therapies. The demographic data abstracted for this analysis included year of publication, acronyms of the study or study title, duration of the study period, type of study (phase II/III), primary and secondary endpoints, number of patients included, median age, sex (male/female), ECOG Performance status (0,1,2), tumor stage (loco-regional disease; stage I–III and metastatic disease; stage IV), and tumor pathology (epithelioid, biphasic, sarcomatoid). Overall survival (OS), 1-year and 2-year OS rates,
progression free survival (PFS), and objective response rate (ORR) were the outcomes evaluated. The radiological response data included patients having complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), and disease control rate (DCR). The toxicity summary included patients with grade 3–4 toxicities and was subdivided into toxicity category (i.e., general, blood and lymphatic system, cardiac, gastro-intestinal, infections, respiratory, and skin).

2.2. Outcome Measures and Statistical Analysis

The primary outcomes were OS and PFS; extracted medians of these variables were transferred into a logarithm scale [9]. The random-effects model described by DerSimonian and Laird [10] was used for this analysis. For primary and secondary outcomes, corresponding forest plots were created. Study heterogeneity was assessed using $I^2$ statistics. Values of 0–30%, 31–60%, 61–75%, and 76–100% indicated low, moderate, substantial, or considerable heterogeneity, respectively [11]. All analyses were performed in R (Version 4.0, R Foundation for Statistical Computing, Vienna, Austria). For identifying publication bias, funnel plots and the Egger test were used. Statistical significance of $p < 0.05$ indicated the presence of bias. To investigate the potential effects of each of the prognostic variables on OS, patient characteristics were also extracted from each study and included as predictors in the meta-regression model. Considered variables include median age, gender, ECOG performance status, tumor stage, and tumor pathology. The extent to which the meta-regression model explained heterogeneity of the effect among studies was quantified by the percentage reduction of between-study variability. Plot of residuals was used to check the adequacy of the meta-regression model. Nomograms were used to represent results of the meta-regression model, estimating survival time using the covariates. In developing the nomogram, we used model coefficients to assign points to characteristics and predictions from the model to map cumulative point totals. Finally, the nomogram was used to predict the overall survival outcomes reported in the positive phase II reports (STELLAR [12] study) and phase III studies (MAPS [13] and CheckMate 743 [4]) and compared to the original results to assess the model performance.

3. Results

Twenty-four phase II studies and five phase III trials were included in this meta-analysis with outcomes data collected on 2534 patients (Figure S1). Key patient characteristics, demographics, and treatment information were not uniformly or consistently reported across the literature. However, there was no publication bias detected ($p > 0.05$) across the included studies regarding the primary outcomes evaluated in this meta-analysis (Figure S2).

3.1. Demographic Data of Platinum-Pemetrexed Regimen

Ten trials ($n = 1303$ patients) included a platinum-pemetrexed-based treatment regimen with a median of 89 patients in each study (range: 11–302 patients) (Table 1). Across all studies, 81% were male, and the median age was 66 years (range: 59–72 years). The majority of patients (60%) had an ECOG status of 1. The patients diagnosed with loco-regional disease and metastatic disease were 35% and 47%, respectively. The majority of patients across all studies were epithelioid (80%), followed by biphasic (11%), and sarcomatoid (8%).
### Table 1. Demographic data of malignant pleural mesothelioma patients treated with cisplatin/carboplatin and pemetrexed.

| Author                  | Year | Acronymous | Duration   | Type of Study | Treatment                  | Primary End Point | Secondary Endpoint | N     | Median Age | Sex (No.%) | ECOG Performance Status (No.%) | Tumor Stage | Tumor Pathology |
|-------------------------|------|------------|------------|--------------|----------------------------|-------------------|--------------------|-------|------------|------------|-------------------------------|-------------|-----------------|
| Vogelzang et al. [6]    | 2003 | NA         | 1999–2001  | III          | Cisplatin + Pemetrexed     | OS, PFS, RR, duration of response | 226               | 61     | 36         | 164 (97%) | 42 (13%) NA NA NA 73 (32%) 102 (45%) 154 (66%) 27 (10%) | Loco-Regional (Stage I–III) | Epithelioid | Sarcomatoid |
| Cerrochi et al. [7]     | 2006 | NA         | 2002–2005  | II           | Carboplatin + Pemetrexed   | ORR, toxicity, TTP, and OS | 102               | 65     | 101        | 76 (75%) 28 (25%) 35 (32%) 61 (60%) 5 (5%) 34 (33%) 49 (48%) 80 (78%) 9 (9%) | Metastatic (Stage IV) | Epithelioid | Biphasic | Sarcomatoid |
| Castagneto et al. [14]  | 2008 | NA         | 2003–2005  | II           | Carboplatin + Pemetrexed   | RR, OS, TTP, Toxicity | 75                | 65     | 100        | 54 (71%) 22 (29%) NA NA NA 27 (30%) 56 (48%) 57 (79%) 73 (97%) 3 (3%) | Epithelioid | Biphasic | Sarcomatoid |
| Katarzynszka et al. [15] | 2010 | NA         | 2004–2007  | II           | Carboplatin + Pemetrexed   | RR, OS, TTP | 62                | 66     | 100        | 53 (86%) 9 (14%) 25 (40%) 37 (60%) 0 23 (37%) 17 (27%) 47 (76%) NA 15 (24%) | Epithelioid | Biphasic | Sarcomatoid |
| Krug et al. [16]        | 2014 | NA         | 2003–2005  | II           | Carboplatin + Pemetrexed   | RR, OS, TTP, Toxicity | 76                | 65     | 100        | 54 (71%) 22 (29%) NA NA NA 27 (30%) 56 (48%) 57 (79%) 73 (97%) 3 (3%) | Epithelioid | Biphasic | Sarcomatoid |
| Buikhuisen et al. [17]  | 2016 | NA         | 2009–2012  | II           | Carboplatin + Pemetrexed   | RR, OS, PFS | 11                | 59     | 100        | 10 (60%) 1 (11%) 7 (39%) 16 (70%) 0 NA NA NA NA 10 (60%) 1 (11%) | Epithelioid | Biphasic | Sarcomatoid |
| Zalcman et al. [18]     | 2016 | MAPS       | NA         | III          | Carboplatin + Pemetrexed   | OS, PFS, QoL, and safety | 225               | 66     | 100        | 169 (76%) 60 (26%) 96 (43%) 131 (57%) 90 (39%) 103 (46%) 223 (97%) 6 (3%) NA | Epithelioid | Biphasic | Sarcomatoid |
| Tao et al. [19]         | 2019 | SWOG 50965 | 2013–2016  | II           | Carboplatin + Pemetrexed   | ORR, OS, QoL, and toxicity | 47                | 72     | 100        | 40 (85%) 7 (15%) NA NA NA NA NA 35 (74%) 12 (26%) NA | Epithelioid | Biphasic | Sarcomatoid |
| Scagliotti et al. [19]  | 2019 | LUME-Meso  | 2016–2018  | III          | Carboplatin + Pemetrexed   | OS, ORR, ORR, DCR, QoL, | 229               | 66     | 100        | 169 (76%) 60 (26%) 96 (43%) 131 (57%) 90 (39%) 103 (46%) 223 (97%) 6 (3%) NA | Epithelioid | Biphasic | Sarcomatoid |
| Baas et al. [4]         | 2021 | CheckMate 743 | 2016–2018 | III          | Carboplatin/Carboplatin + Pemetrexed | OS, ORR, DCR | 302               | 69     | 100        | 233 (77%) 69 (23%) 124 (42%) 173 (57%) 106 (35%) 149 (49%) 227 (75%) 39 (13%) 36 (12%) | Epithelioid | Biphasic | Sarcomatoid |

Abbreviations: OS = overall survival; PFS = progression free survival; ORR = objective response rate; RR = response rate; TTP = time to progression; DCR = disease control rate; QoL = quality of life, ECOG = Eastern Cooperative Oncology Group; NA = not available.
3.2. Treatment Outcomes, Radiological Response, and Toxicity Summary Data of Platinum-Pemetrexed Regimen

Treatment with a platinum-pemetrexed-based regimen resulted in a pooled PFS of 6.7 months (95% CI: 6.2–7.2 months) and an OS of 14.2 months (95% CI: 12.7–15.9) (Figure 1A,B).

**Figure 1.** Forest plots demonstrating the (A) progression-free survival with platinum/pemetrexed; (B) overall survival with platinum/pemetrexed; (C) progression-free survival with other experimental therapies; and (D) overall survival with other experimental therapies. Squares indicate the proportions from individual studies and horizontal lines indicate the 95% confidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using the random effects model. The diamond indicates the pooled proportion with 95% CI.

Across all studies, the proportion of ORR was 24% (95% CI: 12–35%) and DCR was 73% (95% CI: 56–90%) (Table 2). Across all patients, the proportion of individual response rates for CR was 1.5% (95% CI: 1–4%), 19% PR (95% CI: 10–27%), 53% SD (95% CI: 37–69%), and 31% PD (95% CI: 14–48%).
Table 2. Treatment outcomes, radiological response, and toxicity summary for malignant pleural mesothelioma patients treated with cisplatin/carboplatin and pemetrexed.

| Author            | Year | N    | 1 Yr. Survival Rates (Months) | 2 Yr. Survival Rates (Months) | Objective Response Rate (ORR) | Complete Response | Partial Response | Stable Disease | Progressive Disease | Disease Control Rate (%) | Objective Response Rate [N (%)] | Radiological Response Rate [N (%)] | Toxicity Summary [Grade 3 and 4] [N (%)] |
|-------------------|------|------|-------------------------------|-------------------------------|-------------------------------|---------------------|------------------|----------------|---------------------|-----------------------------|----------------------------------|-----------------------------------|----------------------------------|
| Vogelzang et al.  | 2005 | 226  | 12.1                          | 6                             | NA                            | NA                  | NA               | NA             | NA                  | 11 (5%)                     | NA                               | NA                               | NA                               |
| Ceresoli et al.   | 2006 | 102  | 12.7                          | 6.5                           | NA                            | NA                  | NA               | NA             | NA                  | 5.7 (41.3)                  | 46 (47%)                         | 29 (28%)                         | 33 (33%)                         |
| Castagneto et al. | 2008 | 76   | 14                            | NA                            | NA                            | NA                  | NA               | NA             | NA                  | 6.5 (19)                    | 25 (33%)                         | 10 (13%)                         | 9 (12%)                          |
| Katrisopoulos et al. | 2010 | 62   | 14                            | NA                            | NA                            | 7                   | 26               | NA             | NA                  | 4.6 (65%)                   | 15 (24%)                         | 5 (9%)                           | NA                               |
| Krug et al.       | 2014 | 23   | 12.6                          | NA                            | NA                            | 10                  | NA               | NA             | NA                  | 0 (0%)                      | 2 (18%)                          | 8 (73%)                          | NA                               |
| Budzianowski et al. | 2016 | 11   | 18.5                          | NA                            | NA                            | 8.3                 | 18               | NA             | NA                  | 100 (44%)                   | 21 (9%)                          | 2 (1%)                           | 28 (13%)                         |
| Zelman et al.     | 2019 | 47   | 8.5                           | NA                            | NA                            | 5.6                 | 20               | NA             | NA                  | 7 (15%)                     | 9 (20%)                          | 2 (4%)                           | 6 (13%)                          |
| Forst et al.      | 2019 | 229  | 16.1                          | NA                            | NA                            | 7                   | 45               | NA             | NA                  | 99 (43%)                    | 54 (24%)                         | NA                               | 10 (4%)                          |
| Buon et al.       | 2021 | 302  | 14.1                          | 8.1                           | 3.8                           | 7.2                 | 45               | NA             | NA                  | 129 (43%)                   | 125 (41%)                        | 14 (5%)                          | 32 (11%)                         |

Abbreviations: OS = overall survival; PFS = progression free survival; yr. = year; ORR = objective response rate; QoL = quality of life; NA = not available; N = number.
The pooled estimates of the treatment-related toxicity outcomes for patients who received a platinum-pemetrexed regimen (Figure 2A-I) with grade 3–4 blood and lymphatic system toxicities were anemia 10% (95% CI: 8–13%), neutropenia 22% (95% CI: 15–30%), and thrombocytopenia 7% (95% CI: 5–10%). Cardiac toxicity was seen in 1% (95% CI: 0–3%), gastro-intestinal toxicity in 3% (95% CI: 1–5%), fatigue in 6% (95% CI: 3–12%), infections in 5% (95% CI: 3–6%), skin toxicity in 1% (95% CI: 0–3%), and nausea and vomiting in 6% (95% CI: 3–10%).

Figure 2. Forest plots demonstrating the toxicity outcomes for platinum/pemetrexed regimen based on toxicity category: (A) Anemia; (B) Neutropenia; (C) Thrombocytopenia; (D) Cardiac Toxicity; (E) Gastro-intestinal toxicity; (F) Fatigue; (G) Infections; (H) Skin toxicity; and (I) Nausea and vomiting. Squares indicate the proportions from individual studies and horizontal lines indicate the 95% confidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using the random-effects model. The diamond indicates the pooled proportion with 95% CI.

3.3. Demographic Data of Experimental Regimens

Nineteen trials tested 15 experimental chemotherapy regimens (n = 1231 patients) in negative phase II or III studies, with a median of 52 patients (range: 20–229 patients) in each study (Table A1). Across these studies, 75% were male, and the median age was 63 years (range: 55–72 years). Patients had an ECOG status of 0 (30%), 1 (60%), and 2 (10%). The patients diagnosed with loco-regional disease and metastatic disease were 39% and 34%, respectively. In these studies, the majority of patients had epithelioid subtype (76%), followed by biphasic (15%), and sarcomatoid (9%).

3.4. Outcomes, Radiological Response, and Toxicity Summary Data of Experimental Regimens

Treatment with these experimental regimens resulted in a pooled estimate of PFS of 6.6 months (95% CI: 6.2–7.0 months) and OS of 13.5 months (95% CI: 12.6–14.6 months) (Figure 1C,D). Across all studies, the proportion of ORR was 31% (95% CI: 26–36%) and the DCR was 76% (95% CI: 69–84%) (Table A2). Responses using these experimental therapies were low: overall proportions for CR were 0.7% (95% CI: 0.3–1.6%), 29% PR (95% CI: 24–34%), 48% SD (95% CI: 42–55%), 22% PD (95% CI: 13–29%).

The pooled toxicity estimates for patients who received experimental chemotherapy regimens (Figure 3A-I) resulted in blood and lymphatic system grade 3–4 toxicities, with
anemia in 4% (95% CI: 2–7%), neutropenia in 21% (95% CI: 12–33%), and thrombocytopenia in 12% (95% CI: 6–24%). Cardiac toxicity was seen in 4% (95% CI: 2–9%), gastro-intestinal toxicity in 4% (95% CI: 2–7%), fatigue in 12% (95% CI: 10–15%), infections in 5% (95% CI: 3–7%), skin toxicity in 1% (95% CI: 0–3%), and nausea and vomiting in 9% (95% CI: 6–15%).

Figure 3. Forest plots demonstrating the toxicity outcomes for various experimental regimens: (A) Anemia; (B) Neutropenia; (C) Thrombocytopenia; (D) Cardiac Toxicity; (E) Gastro-intestinal toxicity; (F) Fatigue; (G) Infections; (H) Skin toxicity; and (I) Nausea and vomiting. Squares indicate the proportions from individual studies and horizontal lines indicate the 95% confidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using the random effects model. The diamond indicates the pooled proportion with 95% CI.

3.5. Development of a Prognostic Nomogram to Estimate Survival

Meta-regression analysis was used to estimate survival with treatment with platinum-pemetrexed using covariates known to be associated with OS, including median age, gender, ECOG performance status, tumor stage, and tumor pathology subtype (Figure 4).

Unlike the aforementioned experimental regimens, two randomized phase III trials and one single-arm phase II trial have demonstrated promising outcomes in this disease entity. The Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS) [13] evaluated cisplatin/pemetrexed/bevacizumab compared to cisplatin/pemetrexed, the STELLAR trial [12] evaluated the use of tumor-treating fields (TTFields) in addition to cisplatin/pemetrexed, and recently CheckMate 743 [4] evaluated nivolumab plus ipilimumab compared to cisplatin/carboplatin and pemetrexed. To evaluate the prognostic nomogram developed in this study, we compared the estimated outcomes using the patient populations enrolled onto these studies and the proportion of each of the covariates and compared the nomogram estimates with the published results. For the MAPS study, given the patient population in the experimental arm of the phase III study, the OS estimate from the nomogram was 15.76 months (95% CI: 13.96–17.81 months) compared to the reported 18.8 months in the study. Similarly, the OS estimate from the nomogram using the CheckMate 743 trial was 13.65 months (95% CI: 11.41–16.33 months) compared to
18.1 months reported in the experimental arm. Therefore, the results of the experimental arms of these two studies were outside the confidence interval estimate based on historical data and consistent with a positive outcome. For the STELLAR trial, the OS estimate from the nomogram was 16.95 months (95% CI: 10.49–27.38 months) and given the wide confidence interval, potentially could overlap with the 18.2 months reported in the study.

Figure 4. Nomogram model developed to predict overall survival (OS) in patients with malignant pleural mesothelioma treated with platinum/pemetrexed therapy. The mean log OS can be calculated by drawing a vertical line connecting the value of each variable with the point score at the top of the nomogram. The point scores for individual variables are then summed to get a total point score. This is then plotted along the total points line at the bottom of the nomogram. This line is projected to the mean log OS of the trial. Then the exponential of mean log OS is calculated to obtain the OS in months.

4. Discussion

Since 2003, chemotherapy with cisplatin/carboplatin and pemetrexed has been a standard first-line therapy for the majority of newly diagnosed patients who have locally advanced and metastatic MPM [6]. Over the past 15 years, multiple studies have established the outcomes for MPM patients treated with this regimen including single-arm phase II trials [7,14,15], the experimental arms of randomized trials compared to cisplatin alone [6], and the control arms of randomized trials testing novel experimental regimens [4,13,17–20]. In total, 1303 patients have been treated with this regimen across 10 studies, the data of which were abstracted in this systematic review and meta-analysis to determine pooled estimates of a PFS of 6.7 months and an OS of 14.2 months. In fact, a similar number—1231 patients—have been treated with experimental regimens who showed no improved outcomes compared to these historical estimates, underscoring the need for novel therapeutic development in this space. Moreover, despite advances in this field with the addition of bevacizumab and immunotherapy, doublet chemotherapy remains to be commonly used in most parts of the world where mesothelioma incidence continues to rise. Although the addition of bevacizumab to first-line chemotherapy has been added to the national guidelines [13], this regimen has not received FDA approval. Moreover, in CheckMate 743, nivolumab and ipilimumab were compared to pemetrexed-platinum, and although the OS was extended in the experimental arm, subgroup analysis yielded important caveats [4].
For example, for patients with epithelioid histologies (75% of those enrolled), the 12-month OS rates were not as striking (66% vs. 69%). Similarly, for those patients with a PDL-1 < 1%, the Kaplan-Meier curves crossed with longer follow-up, yielding an overall hazard ratio of 0.94. Hence, the role of first-line chemotherapy continues to be evaluated in ongoing trials.

Randomized controlled trials (RCTs) are deemed the gold standard of clinical research [21]. Randomization is often recommended for endpoints with a higher risk of confounding and selection bias, and it has been shown to improve the ability of phase II results to accurately predict phase III success [22,23]. However, modifications to traditional randomized trial designs have been performed to improve their performance in clinical practice. For example, the permuted block randomization has been widely used; however, in this design, there exists a compromise between effective imbalance control with a small block size and accurate allocation target with large block size [24]. Several alternative randomization designs have been proposed, such as the maximal procedure, brick tunnel randomization, and block urn designs [25–27]. However, for cancers such as mesothelioma, there are several logistical constraints for patients with rare diseases, as well as accrual/drop-out issues for those randomized to standard arms with known historically poor outcomes. Therefore, in other similar rare disease entities with robust historical survival estimates, there has been a resurgence in the consideration of alternative clinical trial designs [28]. Bayesian randomized designs and multi-arm multi-stage designs are two different approaches for improving reliability by using patient outcomes [29]. The Bayesian design allocates a greater proportion of prospective patients to well-performing treatments, whereas the multi-arm multi-stage designs use pre-specified stopping boundaries to discontinue novel treatments due to lack of efficacy. Although the Bayesian randomized designs have been shown to be more effective than traditional RCTs in multi-arm studies, their efficiency improvements in two-arm studies have been modest, especially if the rate of accrual outpaces the event rate, since the latter is required to modified the “prior” in a Bayesian concept [29]. Some studies examined the effects of phase II designs for binary endpoints on subsequent phase III trials, and found that randomization is useful when interstudy variability is high or there is a tendency to underestimate the control response [30]. Therefore, there is continued need to develop novel methods of clinical study and pooling historical data may help in future with future trial designs.

Meta-regression, the technique used in this study to develop the nomogram, is often used to assess the relationship between one or more covariates and a dependent variable. Similar approaches can be performed with a meta-analysis alone; however the covariates are at the level of the study rather than the level of the subject [31]. The differences that we need to address as we transition from using primary study data to meta-analysis for regression are similar to those for subgroup analyses. For example, in this meta-analysis, using meta-regression, we identified variables that were associated with OS and developed a nomogram to determine the influence of each of these on survival, including median age, gender, ECOG performance status, tumor stage, and tumor pathology. Using the nomogram, the overall survival was predicted as reported in the positive phase II and III studies and compared to the original result reported in these studies.

In the MAPS study [13], the patient population in the experimental arm of the phase III study showed an OS estimate from the nomogram to be 15.76 months (95% CI: 13.96–17.81 months), as compared to the 18.8 months that was reported in the original study. Similarly, for another phase III study (CheckMate 743) [4], the OS estimate from the nomogram was 13.65 months (95% CI: 11.41–16.33 months), as compared to 18.1 months reported in the study. Based on the nomogram model developed from historical estimates, the OS reported for the positive phase III trials are outside of the 95% confidence interval range of the historical estimates; however, the predicted OS from the nomogram was also similar to the OS from the control arms in the original studies, indicating good performance. Interestingly, in the single-arm phase II STELLAR study [12], the OS estimate from the nomogram was 16.95 months (95% CI: 10.49–27.38 months), compared to 18.2 months. The OS reported in this study falls within the range of the 95% confidence interval predicted
from the nomogram. This demonstrates the importance of patient numbers in phase II trials, as the effectiveness of a phase II trial cannot be measured due to the wide confidence interval, prompting well-powered confirmatory studies. A well-designed phase II trial with complete reporting of the trial design, patient eligibility, study endpoints, and statistical analyses may be reliable and applicable in rare diseases, such as MPM [32].

There are important limitations to our analysis that should be noted. Formally, any categorical variable should have specific outcome-specific data to optimize the performance of the meta-regression. For example, for gender, male-specific OS and female-specific OS should be calculated. Unfortunately, this was difficult to extract from existing publications, since this level of detail is seldom reported. Similarly, Brims et al. [33] developed a prediction model for MPM using variables like Hb, weight loss, and albumin, which was unable to be extracted from existing publications for this study but would likely improve the performance of the survival estimates. However, in this study, we included percentages as continuous variables in the meta-regression. Furthermore, individual patient-level data can also be used to enhance any created model and should be pursued in subsequent studies. Given this promising approach with study-level data, further projects using individual patient-level data should be performed.

5. Conclusions

Given the rare incidence of MPM and the aggressive nature of the disease course, innovative clinical trial designs with significantly weighted randomization to experimental regimens can be utilized using robust survival estimates from prior studies. This study provides baseline comparative values and also allows for accounting for differing proportions of known prognostic variables. Collaborative efforts can drive change in the right direction, and appreciable progress has to be facilitated. Newer trial designs may be needed to pave the way for future innovations in this rare disease.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13092186/s1, Figure S1: PRISMA flow diagram showing the selection of studies for the systematic review of malignant pleural mesothelioma patients treated in the first-line setting with combination chemotherapy regimens, Figure S2: Funnel plots for (A) progression-free survival with platinum/pemetrexed, (B) overall survival with platinum/pemetrexed, (C) progression-free survival with other experimental therapies, and (D) overall survival with other experimental therapies to assess the potential for publication bias.

Author Contributions: Conception and Design: R.K., R.T. & M.R. Analysis: M.R. Critical Review of Manuscript: R.K., R.T., M.R., H.A., F.A., P.K., E.W.A., M.C.T., M.P.M. All authors have read and approved the manuscript.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: R.K.: Honoraria from Accuray Inc., Elekta AB, Viewray Inc., Novocure Inc., Elsevier Inc. Institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, Viewray Inc.; H.A.: Honoraria from Novocure Inc.; F.A.: Speaker’s Bureau for Eli Lilly and Company and Boehringer Ingelheim; M.T.: Institutional research funding from Blue Earth Diagnostics Ltd; M.P.M.: Consulting for Karyopharm, Sapience, Zap, Mevion. Board of Directors: Oncocutectics. Other authors declare no conflict of interest.
### Appendix A

#### Table A1. Demographic data for patients with malignant pleural mesothelioma treated with experimental therapies, negative on phase II/III studies.

| Author et al. [16] | Year | Acronyms | Duration | Type of Study | Treatment | Primary End Point | Secondary Endpoint | N   | Median Age | Sex [No.(%)] | ECOG Performance Status [No.(%)] | Tumour stage | Tumour Pathology |
|-------------------|------|----------|----------|---------------|-----------|-------------------|-------------------|-----|-------------|----------------|-----------------------------------|--------------|----------------|
| Nowak et al. [34] | 2002 | NA       | NA       | II            | Cisplatin + Gemcitabine | ORR          | PFS, OS, QoL    | 53  | 63         | 45 (85%)     | 8 (15%)                                      | 17 (32%)     | 31 (59%)        | 5 (9%)     | 33 (62%)               | 15 (25%)     | 42 (79%)       | 2 (4%)     | 7 (13%)         |
| Van Haarst et al. [35] | 2002 | NA       | April 1999–Dec 1999 | II | Cisplatin + Gemcitabine | ORR          | PFS, OS, QoL    | 32  | 56         | 27 (84%)     | 5 (14%)                                      | 5 (14%)     | 26 (85%)        | 1 (1%)     | 15 (48%)               | 15 (41%)     | 26 (82%)       | 3 (9%)     | 3 (9%)          |
| Furacchio et al. [36] | 2003 | NA       | 1996–2000 | II | Carboplatin + Gemcitabine | RR | OS, PFS, Toxicity | 30  | 60         | 34 (60%)     | 18 (32%)                                      | 11 (22%)     | 33 (66%)        | 4 (12%)    | 11 (22%)               | 12 (24%)     | 34 (68%)       | 13 (26%)   | 3 (6%)           |
| Schulte et al. [37] | 2003 | NA       | 1999–2001 | II | OxaPlitin + Gemcitabine | ORR | OS, PFS, Toxicity | 23  | 65         | 18 (72%)     | 7 (28%)                                      | 7 (28%)     | 13 (52%)        | 5 (20%)    | 13 (52%)               | 10 (25%)     | 16 (64%)       | 8 (32%)    | 1 (3%)          |
| Van Meersbeeck et al. [38] | 2005 | NA       | NA       | III | Cisplatin + Raltitrexed | OS | PFS, RR, safety, QoL | 126 | 59         | 104 (85%)    | 22 (17%)                                      | 32 (25%)     | 77 (61%)        | 17 (14%)   | NA                     | NA         | 95 (75%)       | 18 (14%)   | 5 (4%)          |
| Castagneto et al. [39] | 2005 | NA       | 1999–2001 | II | Cisplatin + Gemcitabine | ORR          | PFS, OS, PFS    | 35  | 61         | 21 (60%)     | 14 (40%)                                      | 7 (22%)     | 33 (66%)        | 2 (6%)     | 8 (23%)                 | 13 (8%)      | 26 (82%)       | 3 (9%)     | 3 (9%)          |
| Fennell et al. [40] | 2005 | NA       | NA       | II | Oxaliplatin + Vinorelbine | ORR          | OS, PFS, Toxicity | 26  | 65         | 18 (87%)     | 5 (13%)                                      | 6 (16%)     | 15 (68%)        | 5 (13%)    | 6 (16%)                 | 15 (79%)     | 7 (18%)        | 13 (8%)    | 13 (8%)         |
| Berghmans et al. [41] | 2005 | NA       | 1998–2003 | II | Cisplatin + Epirubicin | ORR          | Toxicity and OS | 69  | 62         | 59 (89%)     | 10 (7%)                                           | NA         | NA                     | NA         | 18 (12%)               | 23 (19%)     | 43 (74%)       | 6 (10%)    | 9 (16%)         |
| Kalmah et al. [42] | 2008 | SWOG-9810 | 1999–2000 | II | Cisplatin + Gemcitabine | OS | ORR, Toxicity | 50  | 69         | 44 (88%)     | 6 (12%)                                      | 13 (26%)    | 27 (54%)        | 10 (20%)   | NA                     | NA         | 25 (50%)       | 3 (6%)     | 4 (8%)          |
| Dowell et al. [43] | 2012 | NA       | NA       | II | Cisplatin + Pemetrexed + Bevacizumab | PFS | RR, OS and toxicity | 52  | 64         | 44 (88%)     | 18 (35%)                                      | 17 (33%)    | 36 (54%)        | 6 (12%)    | 15 (29%)               | 13 (25%)     | 16 (44%)       | 8 (32%)    | 1 (3%)          |
| Kovac et al. [44] | 2012 | NA       | 2002–2008 | II | Cisplatin + Gemcitabine | RR | OS, PFS, Toxicity | 78  | 56         | 58 (74%)     | 20 (26%)                                      | 14 (18%)    | 51 (65%)        | 13 (17%)   | 38 (46%)               | 22 (29%)     | 56 (72%)       | 15 (19%)   | 4 (5%)          |
| Kindler et al. [45] | 2012 | NA       | 2001–2005 | II | Cisplatin + Gemcitabine | RR | OS, PFS, Toxicity | 53  | 62         | 39 (73%)     | 14 (27%)                                      | 24 (46%)    | 29 (55%)        | NA         | NA                     | NA         | 39 (74%)       | 14 (26%)   | NA             |
| Ceremolo et al. [46] | 2013 | NA       | 2007–2009 | II | Carboplatin + Pemetrexed + Bevacizumab | PFS | Toxicity, RR and OS | 77  | 67         | 49 (64%)     | 27 (36%)                                      | 39 (52%)    | 16 (24%)        | NA         | NA                     | NA         | 6 (9%)         | 6 (9%)     | 5 (7%)          |
| O’Donohue et al. [47] | 2014 | NA       | 2007–2010 | II | Carboplatin + Pemetrexed + Bevacizumab | PFS | RR, ORR and OS | 55  | 60         | 50 (90%)     | 30 (60%)                                      | NA         | 30 (60%)        | 30 (60%)   | 20 (40%)                | 20 (40%)     | 60 (100%)      | 30 (60%)   | 30 (60%)        |
| Hassan et al. [48] | 2014 | NA       | 2009–2010 | II | Cisplatin + Pemetrexed + Bevacizumab | ORR | OS, PFS, safety | 39  | 67         | 69 (75%)     | 20 (25%)                                      | NA         | NA                     | NA         | 35 (86%)               | 45 (88%)     | 79 (99%)       | 10 (11%)   | NA             |
| Krug et al. [49] | 2014 | NA       | NA       | II | Cisplatin + Pemetrexed + Bevacizumab | PFS | OS, DCR, and safety | 40  | 64         | 32 (80%)     | 8 (20%)                                      | 14 (35%)    | 25 (63%)        | 1 (25%)    | NA                     | NA         | 31 (75%)       | 6 (15%)    | 4 (10%)         |
| Buikhuizen et al. [50] | 2016 | NA       | 2009–2012 | II | Cisplatin + Pemetrexed + Axitinib | ORR | OS, PFS | 20  | 63         | 15 (75%)     | 5 (25%)                                      | NA         | NA                     | NA         | 16 (80%)               | 2 (10%)      | 2 (10%)        | NA         | NA             |
| Tao et al. [51] | 2019 | SWOG-50005 | 2015–2016 | II | Cisplatin + Pemetrexed + Bevacizumab | PFS | OS, DCR, and safety | 48  | 72         | 38 (84%)     | 7 (16%)                                      | NA         | NA                     | NA         | NA                     | NA         | 34 (70%)       | 13 (26%)   | NA             |
| Seghetti et al. [52] | 2019 | LUME-Meso | 2016–2018 | III | Cisplatin + Pemetrexed + Bevacizumab | PFS | OS, ORR, DCR, and QoL | 229 | 66         | 105 (72%)    | 64 (28%)                                      | 99 (43%)    | 130 (57%)       | NA         | 89 (59%)               | 113 (40%)    | 220 (96%)      | 9 (4%)     | NA             |

**Abbreviations:** OS = overall survival; PFS = progression free survival; ORR = objective response rate; RR = response rate; TTP = time to progression; DCR = disease control rate; QoL = quality of life; ECOG = Eastern Cooperative Oncology Group; NA = not available.
## Table A2. Treatment outcomes, radiological response, and toxicity summary for malignant pleural mesothelioma patients treated with experimental therapies, negative on phase II/III studies.

| Author               | Year | OS (Months) | 1 yr. Survival Rate | 2 yr. Survival Rate | PFS (Months) | Objective Response Rate (ORR %) | Radiological Response Rate [No. (%)] | Toxicity summary (Grade 3 and 4) |
|----------------------|------|-------------|---------------------|---------------------|--------------|---------------------------------|--------------------------------------|-----------------------------------|
|                       |      |             |                     |                     |              | Complete Response | Partial Response | Stable Disease | Progressive Disease | Disease Control Rate (%) | Blood and Lymphatic System Disorders | Gastrointestinal Disorders | Cardiac Disorders | Gastrointestinal Disorders | Fatigue | Infections | Respiratory Disorders | Skin Disorders | QoL | Nausea and Vomiting |
|                       |      |             |                     |                     |              |                  |                       |               |                        |                         | Anemia | Neutropenia | Thrombocytopenia |          |           |                        |                |     |                     |
| Nowak et al. [34]    | 2002 | 17.3        | NA                  | NA                  | 6.4          | 33                | 0                      | 17 (33%)        | 31 (60%)                  | 4 (7%)                      | 93     | 2 (7%)       | 30 (50%)       | 26 (48%) | NA | 1 (2%)            | NA             | 2 (4%) | NA                  | NA | 20 (77%) |
| Van Haarst et al. [35]| 2002 | 14.6        | NA                  | NA                  | 6.1          | 16                | 0                      | 4 (16%)         | 18 (72%)                  | 3 (12%)                     | 88     | 4 (13%)     | 2 (6%)         | 4 (15%)  | 1 (3%) | 1 (3%)           | 2 (6%)         | 0   | 0                  | 0  | 9 (29%) |
| Favaretto et al. [36] | 2005 | 15.3        | 8                   | 4.5                 | 9.2          | 26                | 0                      | 13 (26%)        | 29 (58%)                  | 12 (24%)                    | 76     | 8 (10%)      | 12 (16%)       | 17 (24%) | 0   | 0                | 0              | 0   | 0                  | 0  | 0                |
| Schulte et al. [37]  | 2003 | 13          | 6.7                 | NA                  | 7            | 40                | 0                      | 10 (48%)        | 6 (24%)                   | 9 (36%)                     | 64     | 1 (4%)       | 2 (9%)         | 0          | NA | 1 (4%)           | NA             | NA | NA                  | NA | 2 (9%)  |
| Van Meerbeeck et al. [38] | 2005 | 11.4        | 5.2                 | 2.1                 | 5.3          | 24                | 2 (2%)                 | 24 (28%)        | 58 (65%)                  | NA                         | 89     | 4 (13%)     | 9 (21%)       | 2 (2%)     | 2 (2%) | 3 (2%)           | 15 (12%)       | 2 (2%) | NA                  | NA | 18 (14%) |
| Castagneto et al. [39] | 2005 | 13          | NA                  | NA                  | 8            | 26                | 0                      | 9 (36%)         | 14 (40%)                  | 11 (35%)                    | 66     | 6 (26%)     | 21 (63%)      | 18 (52%)  | 0   | 0                | 0              | 0   | 0                  | 0  | 12 (35%) |
| Fornell et al. [40]  | 2005 | 10.4        | 2.8                 | NA                  | 7.8          | 23                | 0                      | 6 (23%)         | 17 (65%)                  | 3 (12%)                     | 88     | NA          | 5 (18%)       | NA         | NA | 2 (6%)           | 4 (12%)        | 0   | 0                  | 0  | 4 (12%) |
| Bayraktas et al. [41] | 2005 | 13.3        | 6.6                 | NA                  | 7.3          | 19                | 0                      | 12 (39%)        | 28 (40%)                  | 24 (38%)                    | 59     | NA          | 57 (94%)      | 2 (3%)     | 1 (2%) | 0                | 0              | 0   | 0                  | 0  | 17 (29%) |
| Katsouli et al. [42] | 2008 | 10          | 3                   | NA                  | 6            | 12                | 1 (2%)                 | 5 (10%)         | 23 (45%)                  | 19 (38%)                    | 62     | 12 (24%)    | 25 (50%)      | 16 (32%)  | NA | 2 (3%)           | 12 (25%)       | 0   | 0                  | 0  | 1 (2%)  |
| Dowell et al. [43]   | 2012 | 14.8        | NA                  | NA                  | 6.9          | 40                | NA                    | NA              | 33 (50%)                  | 6 (11%)                     | 2 (4%)  | NA          | 3 (6%)        | 4 (8%)     | NA | 2 (4%)           | NA             | 2 (4%) | NA                  | NA | 6 (8%)  |
| Koezar et al. [44]   | 2012 | 17          | NA                  | NA                  | 8            | 50                | 4 (8%)                 | 35 (62%)        | 35 (58%)                  | 4 (5%)                      | 95     | 2 (3%)      | 18 (33%)      | NA         | NA | NA                 | NA            | NA | NA                  | NA | 1 (2%)  |
| Kandir et al. [45]   | 2012 | 15.6        | 9.1                 | 4.8                 | 6.9          | 25                | 0                      | 13 (25%)        | 27 (53%)                  | 12 (28%)                    | 75     | 2 (4%)      | 22 (44%)      | 20 (38%)  | NA | 3 (6%)           | NA             | 5   | 1 (10%)          | NA | NA |
| Comussi et al. [46]  | 2013 | 15.3        | 9.5                 | 3.9                 | 6.9          | 34                | NA                    | 24 (70%)        | 44 (80%)                  | NA                         | 92     | 3 (4%)      | 6 (9%)        | 2 (3%)     | 2 (3%) | 0                | 6 (9%)         | NA | 1 (1%)            | NA | 2 (3%)  |
| O’Toole et al. [47]  | 2013 | 13.5        | 7.5                 | NA                  | 5            | 27                | 2 (5%)                 | 21 (39%)        | 39 (69%)                  | 16 (28%)                    | 80     | 1 (1%)      | 1 (1%)        | 9 (11%)   | 5 (6%) | 2 (2%)           | 15 (28%)       | 5 (6%) | NA                 | NA | 3 (7%)  |
| Hussein et al. [48]  | 2014 | 14.8        | NA                  | NA                  | 6.1          | 33                | 0                      | 33%             | 62%                      | 8%                          | 75     | 10 (13%)    | 10 (13%)     | 0%         | 2 (3%) | 2 (3%)           | 9 (10%)        | 0   | 3 (6%)            | 4%  | 4 (5%)  |
| King et al. [49]     | 2014 | 13.3        | NA                  | 5.1                 | 31           | 0                 | 12 (21%)               | 15 (28%)        | NA                       | 69 (100%)                   | 6 (25%) | NA          | 1 (3%)        | 1 (3%)    | 0   | 0                | 0              | 0   | 0                  | 0  | 0          |
| Buhatzian et al. [50] | 2016 | 18.9        | NA                  | NA                  | 5.6          | 36                | NA                    | 8 (36%)         | 9 (43%)                   | NA                         | 79     | 1 (1%)     | 9 (48%)       | 1 (3%)     | 1 (1%) | 3 (15%)          | 0 NA           | 0   | 1 (3%)            | NA | 2 (10%) |
| Ito et al. [51]      | 2019 | 10          | NA                  | NA                  | 7.2          | 50                | NA                    | NA              | NA                       | NA                         | NA     | 1 (2%)      | 6 (13%)       | 4 (9%)     | NA | 10 (22%)         | 2 (4%)         | 6 (13%) | NA                  | NA | 4 (9%)  |
| Segalotti et al. [52] | 2019 | 14.4        | NA                  | NA                  | 6.8          | 45                | NA                    | 103 (45%)       | NA                       | NA                         | 91     | 17 (37%)    | 73 (50%)     | NA         | NA | 8 (17%)          | 24 (11%)       | 34  | 9 (6%)            | NA | 1 (1%)  |

Abbreviations: OS = overall survival; PFS = progression free survival; yr. = year; ORR = objective response rate; QoL = quality of life; NA = not available; N = number.
References

1. Robinson, B.W.; Musk, A.W.; Lake, R.A. Malignant mesothelioma. *Lancet* 2005, 360, 397–408. [CrossRef]

2. Delgermaa, V.; Takahashi, K.; Park, E-K.; Le, G.V.; Hara, T.; Sorahan, T. Global mesothelioma deaths reported to the World Health Organization from 1994 and 2004. *Bull. World Health Organ.* 2011, 89, 716–724. [CrossRef]

3. Kindler, H.L.; Ismaiel, N.; Armato, S.G.; Bueno, R.; Hesdorffer, M.; Jahan, T.; Jones, C.M.; Miettinen, M.; Pass, H.; Rimner, A.; et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. *J. Clin. Oncol.* 2018, 36, 1343–1373. [CrossRef]

4. Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S.; et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. *Lancet* 2021, 397, 375–386. [CrossRef]

5. Scagliotti, G.V.; Shin, D.-M.; Kindler, H.L.; Vasconcelles, M.J.; Keppler, U.; Manegold, C.; Burris, H.; Gatzemeier, U.; Blatter, J.; Symanovski, I.T.; et al. Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma. *J. Clin. Oncol.* 2003, 21, 1556–1561. [CrossRef]

6. Vogelzang, N.J.; Rusthoven, J.J.; Symanovski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; et al. Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. *J. Clin. Oncol.* 2003, 21, 2636–2644. [CrossRef] [PubMed]

7. Ceresoli, G.L.; Zucali, P.A.; Favaretto, A.G.; Grossi, F.; Bidoli, P.; Del Conte, G.; Ceribelli, A.; Bearz, A.; Morenghi, E.; Cavina, R.; et al. Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma. *J. Clin. Oncol.* 2006, 24, 1443–1448. [CrossRef] [PubMed]

8. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PloS Med.* 2009, 6, e1000097. [CrossRef] [PubMed]

9. Zang, J.; Xu, J.; Xiang, C.; He, J.; Zou, S. Multi-level Model Synthesis of Median Survival Time in Meta-analysis. *Epidemiology* 2015, 26, e2–e3. [CrossRef] [PubMed]

10. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. *Control. Clin. Trials* 1986, 7, 177–188. [CrossRef]

11. Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* 2002, 21, 1539–1558. [CrossRef]

12. Ceresoli, G.L.; Aerts, J.G.; Dziadziuszko, R.; Ramlau, R.; Cedres, S.; van Meerbeeck, J.P.; Mencoboni, M.; Planchard, D.; Chella, A.; Crino, L.; et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STEMILLAR): A multicentre, single-arm phase 2 trial. *Lancet Oncol.* 2019, 20, 1702–1709. [CrossRef]

13. Zalcman, G.; Mazieres, J.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Moro-Sibilot, C.; Molinier, O.; Corre, R.; Monnet, I.; Gounant, V.; et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. *Lancet* 2016, 387, 1405–1414. [CrossRef]

14. Castagneto, B.; Botta, M.; Aiutini, E.; Spigno, F.; Degiovanni, D.; Alabiso, O.; Serra, M.; Muzio, A.; Carbone, R.; Buosi, R.; et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). *Ann. Oncol.* 2008, 19, 370–373. [CrossRef] [PubMed]

15. Katirtzoglou, N.; Gkiozos, I.; Makrila, N.; Tsaroucha, E.; Rapiti, A.; Stratakos, G.; Fountzilas, G.; Syrigos, K.N. Carboplatin plus pemetrexed in combination with or without bevacizumab in patients with malignant pleural mesothelioma: A phase II study. *Clin. Lung Cancer* 2010, 11, 30–35. [CrossRef] [PubMed]

16. Krug, L.M.; Pass, H.L.; Rusch, V.W.; Kindler, H.L.; Sugarbaker, D.J.; Rosenzweig, K.E.; Flores, R.; Friedberg, J.S.; Pisters, K.; Monberg, M.; et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. *J. Clin. Oncol.* 2009, 27, 3007–3013. [CrossRef]

17. Stephenson, J.; Imrie, J. Why do we need randomised controlled trials to assess behavioural interventions? *BMJ* 1998, 316, 611–613. [CrossRef]
Cancers 2021, 3, 2186

22. Tang, H.; Foster, N.R.; Grothey, A.; Ansell, S.M.; Goldberg, R.M.; Sargent, D.J. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. *J. Clin. Oncol.* 2010, 28, 1936–1941. [CrossRef] [PubMed]

23. Sharma, M.R.; Studer, W.M.; Ratain, M.J. Randomized phase II trials: A long-term investment with promising returns. *J. Natl. Cancer Inst.* 2011, 103, 1093–1100. [CrossRef]

24. Zhao, W. A better alternative to stratified permuted block design for subject randomization in clinical trials. *Stat. Med.* 2014, 33, 5239–5248. [CrossRef] [PubMed]

25. Berger, V.W.; Ivanova, A.; Deloria Knoll, M. Minimizing predictability while retaining balance through the use of less restrictive randomization procedures. *Stat. Med.* 2003, 22, 3017–3028. [CrossRef]

26. Zhao, W.; Meng, Y. Block urn design—a new randomization algorithm for sequential trials with two or more treatments and balanced or unbalanced allocation. *Contemp. Clin. Trials* 2011, 32, 953–961. [CrossRef]

27. Kuznetsova, O.M.; Tymofyeyev, L.; Rajer, M.; Marin, A.; Debeljak, A.; Smrdel, U.; Vrankar, M. A phase II trial of low-dose gemcitabine in patients with non small cell lung cancer. *J. Thorac. Oncol.* 2014, 9, 1316–1323. [CrossRef]

28. Sharma, M.R.; Massard, C.; Cherny, L.; Tishler, V.; Dorkin, H.; Flaherty, K.; Agrawal, S.; Langer, C.; Tan, S.; Wang, Q.; et al. A randomised phase II trial of monoclonal antibody to vascular endothelial growth factor in patients with chemotherapy naive advanced non-squamous non-small cell lung cancer. *Lung Cancer* 2012, 76, 428–433. [CrossRef]

29. Wason, J.M.S.; Trippa, L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. *Stat. Med.* 2010, 29, 3021–3034. [CrossRef] [PubMed]

30. Pond, G.R.; Abbasi, S. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. *Clin. Trials* 2011, 8, 260–269. [CrossRef] [PubMed]

31. Lambert, P.C.; Sutton, A.J.; Abrams, K.R.; Jones, D.R. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. *J. Clin. Epidemiol.* 2002, 55, 86–94. [CrossRef] [PubMed]

32. Tomblyn, M.R.; Rizzo, J.D. Are there circumstances in which phase 2 study results should be practice-changing? *Hematol. Am. Soc. Hematol. Educ. Progr.* 2007, 489–492. [CrossRef] [PubMed]

33. Brims, F.J.H.; Meniawy, T.M.; Duffus, I.; de Fonseka, D.; Segal, A.; Creaney, J.; Maskell, N.; Lake, R.A.; de Klerk, N.; Nowak, A.K. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. *J. Thorac. Oncol.* 2016, 11, 573–582. [CrossRef]

34. Nowak, A.K.; Byrne, M.J.; Williamson, R.; Ryan, G.; Segal, A.; Fielding, D.; Mitchell, P.; Musk, A.W.; Robinson, B.W.S. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. *Br. J. Cancer* 2002, 87, 491–496. [CrossRef] [PubMed]

35. Van Haarst, J.M.W.; Baas, P.; Manegold, C.; Schouwink, J.H.; Burgers, J.A.; De Bruin, H.G.; Mooi, W.J.; Van Klaveren, R.J.; De Jonge, M.J.A.; Van Meerbeeck, J.P. Phase II trial of gemcitabine and cisplatin in malignant pleural mesothelioma. *Br. J. Cancer* 2002, 87, 342–345. [CrossRef] [PubMed]

36. Favaretto, A.G.; Aversa, S.M.L.; Paccagnella, A.; Manzini, V.D.P.; Palmisano, V.; Oniga, F.; Stefani, M.; Rea, F.; Bortolotti, L.; Loreggian, L.; et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study. *Cancer* 2003, 97, 2791–2797. [CrossRef] [PubMed]

37. Schuette, W.; Blankenburg, T.; Lauerwald, K.; Schreiber, J.; Bork, I.; Vollslaeger, B.; Treutler, D.; Schneider, C.P.; Bonnet, R. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. *Clin. Lung Cancer* 2003, 4, 294–297. [CrossRef] [PubMed]

38. Van Meerbeeck, J.P.; Gaafar, R.; Manegold, C.; Van Klaveren, R.J.; Van Marck, E.A.; Vincent, M.; Legrand, C.; Bottomley, A.; Debruyne, C.; Giacone, G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute. *J. Clin. Oncol.* 2005, 23, 6881–6889. [CrossRef]

39. Castagneto, B.; Zai, S.; Dongiovanni, D.; Muzio, A.; Berti, S.; Numico, G.; Botta, M. Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study. *Am. J. Clin. Oncol. Cancer Clin. Trials* 2005, 28, 223–226. [CrossRef] [PubMed]

40. Fennell, D.A.; Steele, J.P.C.; Shamash, J.; Sheaff, M.T.; Evans, M.T.; Goonewardene, T.I.; Nystrom, M.L.; Gower, N.H.; Rudd, R.M. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. *Lung Cancer* 2005, 47, 277–281. [CrossRef]

41. Berghmans, T.; Lafitte, J.J.; Paesmans, M.; Stach, B.; Bercher, M.C.; Wackenber, P.; Lecomte, J.; Collon, T.; Mommen, P.; Sculier, J.P. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. *Lung Cancer* 2005, 50, 75–82. [CrossRef] [PubMed]

42. Kalmadi, S.R.; Rankin, C.; Kraut, M.J.; Jacobs, A.D.; Petrylak, D.P.; Adelstein, D.J.; Keohan, M.L.; Taub, R.N.; Borden, E.C. Gemcitabine and cisplatin in unresectable malignant pleural mesothelioma: An intergroup study of the Southwest Oncology Group (SWOG 9810). *Lung Cancer* 2008, 60, 259–263. [CrossRef]

43. Dowell, J.E.; Dunphy, F.R.; Taub, R.N.; Gerber, D.E.; Ngov, L.; Yan, J.; Xie, Y.; Kindler, H.L. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. *Lung Cancer* 2012, 77, 567–571. [CrossRef] [PubMed]

44. Kovac, V.; Zwitter, M.; Rajer, M.; Marin, A.; Debelaaj, A.; Smrdel, U.; Vrankar, M. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. *Anticancer Drugs* 2012, 23, 230–238. [CrossRef] [PubMed]

45. Kindler, H.L.; Karrison, T.G.; Gandara, D.R.; Lu, C.; Krug, L.M.; Stevenson, J.P.; Jänne, P.A.; Quinn, D.I.; Koczywlas, M.N.; Brahmer, J.R.; et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. *J. Clin. Oncol.* 2012, 30, 2509–2515. [CrossRef] [PubMed]
46. Ceresoli, G.L.; Zucali, P.A.; Mencoboni, M.; Botta, M.; Grossi, F.; Cortinovis, D.; Zilembo, N.; Ripa, C.; Tiseo, M.; Favaretto, A.G.; et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. *Br. J. Cancer* **2013**, *109*, 552–558. [CrossRef]

47. O’Brien, M.E.R.; Gaafar, R.M.; Popat, S.; Grossi, F.; Price, A.; Talbot, D.C.; Cufer, T.; Ottensmeier, C.; Danson, S.; Pallis, A.; et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment. *Eur. J. Cancer* **2013**, *49*, 2815–2822. [CrossRef] [PubMed]

48. Hassan, R.; Kindler, H.L.; Jahan, T.; Bazhenova, L.; Reck, M.; Thomas, A.; Pastan, I.; Parno, J.; O’Shannessy, D.J.; Fatato, P.; et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. *Clin. Cancer Res.* **2014**, *20*, 5927–5936. [CrossRef] [PubMed]